群组管理模式对提高慢性乙型肝炎患者抗病毒治疗依从性的作用研究

doi:10.3969/j.issn.1672-5069.2018.04.034

Abstract

Yu Aidong, Wang Chuanjie, Li Jianfang. Application of group management by WeChat in improving compliance of patients with chronic hepatitis B receiving nucleos(t)des[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 621-622.

References

[1] 柴艳云,李建国,张新龙,等. 阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察.实用肝脏病杂志,2014,17(3):307-308.
[2] 薛红,李遵清. 群组看病管理模式在社区乙型肝炎患者中的应用效果. 中华现代护理杂志,2014,20(10):1139-1143.
[3] Chang M L,Liaw YF.Hepatitis B flares in chronic hepatitis B:pathogenesis,natural course and management. J Hepatol,2014,61(6):1407-1417.
[4] Lee HW,Kang W,Ahn SH,et al.Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients.J Gastroenterol Hepatol,2014,29(5):1049-1055.
[5] Pellicelli AM, Barbaro G, Francavilla R,et al.Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective,multicenter,nonrandomized,open-label study.Clin Ther,2008,30(2):317-323.
[6] Devi U,Locarnini S.Role of resistance testing during oral antiviral therapy of chronic hepatitis B. Curr Hepat Rep,2012,11(2):55-64.
[7] 侯春艳,杨永峰.慢性乙型肝炎抗病毒治疗新进展.实用肝脏病杂志,2017,20(1):124-128.
[8] Liang X,Bi S,Yang W,et al.Epidemiological serosurvey of hepatitis B in China-Declining HBV prevalence due to hepatitis B vaccination. Vaccine,2009,27(47):6550-6557.
[9] Kuo YH,Chen CH,Wang JH,et al.Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion.Scand J Gastroenterol,2010,45(1):75-81.
[10] Ze E,Baek EK,Lee JJ,et al.Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir,and 1-mg entecavir.Clin Mol Hepatol,2014,20(3):267-273.
[11] Shin JW,Park NH,Jung SW,et al.Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.World J Gastroenterol,2006,12(41):6693-6698.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

Application of group management by WeChat in improving compliance of patients with chronic hepatitis B receiving nucleos(t)des

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments